Class
| • | 2. Biological Sciences | [X] |
Subdivision
| • | 204. Medicine, Surgery, Pathology and Immunology | [X] |
| | 21 | Name: | Dr. Michael Heidelberger | | | Institution: | New York University | | | Year Elected: | 1968 | | | Class: | 2. Biological Sciences | | | Subdivision: | 204. Medicine, Surgery, Pathology and Immunology | | | Residency: | Resident | | | Living? : |
Deceased
| | | Birth Date: | 1888 | | | Death Date: | 6/25/91 | | | | |
| 22 | Name: | Sir Harold Himsworth | | | Institution: | Medical Research Council | | | Year Elected: | 1972 | | | Class: | 2. Biological Sciences | | | Subdivision: | 204. Medicine, Surgery, Pathology and Immunology | | | Residency: | International | | | Living? : |
Deceased
| | | Birth Date: | 1905 | | | Death Date: | 11/1/93 | | | | |
| 23 | Name: | Dr. Charles B. Huggins | | | Institution: | University of Chicago | | | Year Elected: | 1962 | | | Class: | 2. Biological Sciences | | | Subdivision: | 204. Medicine, Surgery, Pathology and Immunology | | | Residency: | Resident | | | Living? : |
Deceased
| | | Birth Date: | 1901 | | | Death Date: | 1/12/97 | | | | |
| 24 | Name: | Dr. Niels Kaj Jerne | | | Institution: | Basel Institute for Immunology | | | Year Elected: | 1979 | | | Class: | 2. Biological Sciences | | | Subdivision: | 204. Medicine, Surgery, Pathology and Immunology | | | Residency: | International | | | Living? : |
Deceased
| | | Birth Date: | 1911 | | | Death Date: | 10/7/94 | | | | |
| 25 | Name: | Dr. Yuet Wai Kan | | | Institution: | University of California, San Francisco | | | Year Elected: | 2009 | | | Class: | 2. Biological Sciences | | | Subdivision: | 204. Medicine, Surgery, Pathology and Immunology | | | Residency: | Resident | | | Living? : |
Living
| | | Birth Date: | 1936 | | | | | | |
Yuet Wai Kan is a graduate of the University of Hong Kong Medical School and is at present the Louis K. Diamond Professor of Hematology at the University of California, San Francisco. He has served on many organizations including as the President of the American Society of Hematology (1990) and currently as Chairman of the Croucher Foundation in Hong Kong that supports science and technology in Hong Kong. He works in the fields of hematology and genetics, and his research led to the innovation of DNA diagnosis that has found wide applications in many human conditions. In recognition of his contributions, he has been elected a member of learned science academies in the United States, Great Britain, Taiwan and China. He has received several honorary degrees and many national awards, including the Lasker Award for Medical Research (1991), international awards from Canada, Italy and Switzerland, and most recently the Shaw Prize in Life Sciences and Medicine from Hong Kong (2004). He was elected a member of the Institute of Medicine in 2011. | |
| 26 | Name: | Dr. Ho-Wang Lee | | | Institution: | National Academy of Sciences, Republic of Korea | | | Year Elected: | 1998 | | | Class: | 2. Biological Sciences | | | Subdivision: | 204. Medicine, Surgery, Pathology and Immunology | | | Residency: | International | | | Living? : |
Deceased
| | | Birth Date: | 1928 | | | Death Date: | July 5, 2022 | | | | | | |
As a medical virologist, Ho-Wang Lee studied Japanese encephalitis (JE) and Korean hemorrhagic fever (KHF), now called Hemorrhagic fever with renal syndrome (HFRS). The first of these was the success of tissue culture of JE virus, immune mechanism of JE and overwintering mechanisms of JE virus in Korea from 1955-68. The second of these was the isolation of etiologic agents, epidemiology and prevention of HFRS from 1969-o 2004. He isolated etiologic agents of HFRS from Apodemus mice and urban rats and named the virus Hantaan and Seoul in 1976 and 1980, respectively. He elucidated epizootiology and epidemiology of HFRS in 1979-85. Hantaan virus is the origin of genus Hantavirus and he proved world-wide distribution of hantaviruses from 1977-2000. In 1990, he and his colleagues developed a simple rapid diagnostic kit and an inactivated vaccine against HFRS. This vaccine was distributed in Asia and thereafter the number of HFRS patients decreased significantly. | |
| 27 | Name: | Dr. John Nichols Loeb | | | Institution: | Columbia University | | | Year Elected: | 1998 | | | Class: | 2. Biological Sciences | | | Subdivision: | 204. Medicine, Surgery, Pathology and Immunology | | | Residency: | Resident | | | Living? : |
Living
| | | Birth Date: | 1935 | | | | | | |
John N. Loeb is Professor Emeritus of Medicine and Special Lecturer in Medicine at Columbia University. He graduated summa cum laude from both Harvard College and Harvard Medical School and after a year of internship at the Massachusetts General Hospital moved to New York City in 1962 for a year as an assistant resident on the Medical Service of the Presbyterian Hospital. After two years as a Research Associate with Gordon M. Tomkins in the Laboratory of Molecular Biology at the Institute of Arthritis and Metabolic Diseases at the National Institutes of Health, he returned to New York as Chief Resident in Medicine at the Presbyterian Hospital and Instructor in Medicine at the College of Physicians & Surgeons of Columbia University. He has remained affiliated with both institutions, where since 2005 he has been Professor Emeritus of Medicine and Special Lecturer in Medicine at Columbia University and continues as an Attending Physician at NewYork-Presbyterian Hospital. Dr. Loeb's research was principally focused on mechanisms of hormone action, the physical chemistry of receptor-ligand interactions and their quantitative relationship to biological response, and the regulation of glucose and monovalent cation transport. In pursuing these studies he chose to maintain only a small laboratory so that he could devote substantial time himself to benchwork, and his work was continuously funded by the National Institutes of Health from 1967 to 1999, support for the final ten years coming from an NIH MERIT award. From 1997 until 2003 he served as Associate Chairman for Research in the Department of Medicine and, from 2003 until his retirement, as Vice Chairman for Academic Affairs. Throughout his career Dr. Loeb has had an abiding interest in teaching both medical students and house staff, and in particular in bedside teaching. He has received numerous awards as a teacher at Columbia and additionally has devoted substantial time to teaching abroad. He received a Distinguished Service Award from the College of Physicians and Surgeons in 2007. Major non-scientific interests include nineteenth-century English and French literature and playing chamber music. Dr. Loeb was elected a member of the American Philosophical Society in 1998. | |
| 28 | Name: | Dr. Paul A. Marks | | | Institution: | Memorial Sloan-Kettering Cancer Center | | | Year Elected: | 2007 | | | Class: | 2. Biological Sciences | | | Subdivision: | 204. Medicine, Surgery, Pathology and Immunology | | | Residency: | Resident | | | Living? : |
Deceased
| | | Birth Date: | 1926 | | | Death Date: | April 28, 2020 | | | | | | |
Paul A. Marks was President Emeritus of Memorial Sloan-Kettering Cancer Center (MSKCC) and a member of the Sloan-Kettering Institute for Cancer Research. He was president and CEO of MSKCC from 1980-99. He received his A.B. and M.D. degrees from Columbia University and completed postdoctoral training at the National Institutes of Health, Bethesda, Maryland and the Pasteur Institute, Paris. Following his period at the Pasteur, Dr. Marks returned to Columbia College of Physicians and Surgeons as an assistant professor and was promoted to professor of medicine in 1967. In 1968 he was made professor of human genetics and Frode Jensen Professor of Medicine (1968-80) and the first chairman of the newly created Department of Human Genetics and Development. In 1970 he was elected Dean of the Faculty of Medicine (1970-73). In 1973 he became vice president of health sciences and director of the Comprehensive Cancer Center (1973-80) at Columbia University. In 1980 he was recruited to be the first president and CEO of the combined Memorial Hospital and Sloan-Kettering Institute. He retired from these positions in December 1999. Since January 2000 he has been a member of the Sloan-Kettering Institute, pursuing his research as head of the Laboratory of Cancer Cell Biology.
Dr. Marks published over 400 scientific articles in various scholarly journals. His research focused on the discovery and development of approaches to selectively arrest cancer cell growth. He and his colleagues identified a series of small molecules - hydroxamic acid based hybrid polar compounds - that inhibit histone deacetylases (HDAC), enzymes that play a role in regulating gene expression, cell growth, and cell death and can cause death of a variety of cancer cells, with little or no toxicity to normal cells. SAHA was approved by the Food and Drug Administration for the treatment of cutaneous T-cell lymphoma (CTCL) in October 2006. The first of these novel targeted histone deacetylase inhibitors to be approved for patient use. HDAC inhibitors represent a new approach to cancer therapy.
Dr. Marks was a member of the National Academy of Sciences and the Institute of Medicine and a fellow of the American Academy of Arts & Sciences. He served on many governmental and non-governmental committees and boards, including the President's Commission on Three Mile Island, the President's National Cancer Advisory Board, Councils of the National Academies and the boards of several academic institutions in the USA and abroad. He received a number of honors including the Distinguished Achievement Medal of Columbia University; the Japan Foundation for the Promotion of Cancer Research Medal; the Centenary Medal of the Pasteur Institute; honorary degrees from several universities, including his alma mater, Columbia University, the John Stearns Award for Lifetime Achievement in Medicine of the New York Academy of Medicine; and the President's National Medal of Science (USA). Dr. Marks was a founder of the biotechnology company Aton Pharma, Inc. that had an exclusive license from Columbia to develop SAHA as a cancer therapeutic, which is now a wholly owned subsidiary of Merck.
Paul A. Marks was elected a member of the American Philosophical Society in 2007. He died April 28, 2020 in New York, New York, at the age of 93. | |
| 29 | Name: | Dr. Francis D. Moore | | | Institution: | Harvard Medical School & Brigham & Women's Hospital | | | Year Elected: | 1998 | | | Class: | 2. Biological Sciences | | | Subdivision: | 204. Medicine, Surgery, Pathology and Immunology | | | Residency: | Resident | | | Living? : |
Deceased
| | | Birth Date: | 1913 | | | Death Date: | November 24, 2001 | | | | |
| 30 | Name: | Sir Peter Morris | | | Institution: | The Royal College of Surgeons of England; University of Oxford | | | Year Elected: | 2002 | | | Class: | 2. Biological Sciences | | | Subdivision: | 204. Medicine, Surgery, Pathology and Immunology | | | Residency: | International | | | Living? : |
Living
| | | Birth Date: | 1934 | | | | | | |
Sir Peter Morris supplemented his medical education in Melbourne, Australia, with training at Guy's Hospital in London and the Massachusetts General Hospital. He returned to the University of Melbourne and obtained a Ph.D. in immunology in 1972. From 1974-2001, he was the Nuffield Professor of Surgery, chairman of the Department of Surgery, and director of the Oxford Transplant Centre at the University of Oxford. In 2001 he became President of the Royal College of Surgeons of England and chairman of the Council of the Institute of Health Sciences at the University of Oxford. He is also currently chairman of the British Heart Foundation and Director of the Centre for Evidence in Transplantation at the Royal College of Surgeons. His more than 700 papers deal with the entire field of clinical and experimental transplantation and immunology. He has contributed especially to the study of mechanisms of rejection, tolerance induction and pancreatic islet transplantation. He is one of the distinguished surgeon scientists of our time. In addition to his work in transplantation, in the earlier part of his career he made many contributions to knowledge of the association between HLA and disease, as well as playing a major part in the early anthropological studies of HLA around the Pacific rim. He is the editor of Kidney Transplantation: Principles and Practice, which is now in its 5th edition, and the widely acclaimed Oxford Textbook of Surgery, which is in its 2nd edition. Sir Peter Morris has received many honors, including the Medawar Medal, the Lister Medal and the Hunterian Medal. In 1996 he received knighthood from the Queen for services to medicine, and in 2004 he was made a Companion of the Order of Australia. He is a fellow of the Royal Society and a foreign member of the Institute of Medicine of the National Academy of Sciences. He served as president of the International Transplantation Society, the British Transplantation Society, the European Surgical Association and the International Surgical Society. He was elected a member of the American Philosophical Society in 2002. | |
| 31 | Name: | Dr. David G. Nathan | | | Institution: | Dana-Farber Cancer Institute & Harvard Medical School | | | Year Elected: | 1999 | | | Class: | 2. Biological Sciences | | | Subdivision: | 204. Medicine, Surgery, Pathology and Immunology | | | Residency: | Resident | | | Living? : |
Living
| | | Birth Date: | 1929 | | | | | | |
David Nathan is one of the most distinguished pediatric hematologists in the country. He has spent his career at Harvard University, where he has been a professor of medicine and professor of pediatrics, and in 1985 he was appointed Pediatrician-in-Chief at Childrens Hospital in Boston. In 1995 he became President of the Dana-Farber Cancer Institute. Dr. Nathan has brought to his position scientific excellence, great integrity and a warm humanity. Among other awards he has received the National Medal of Science (1990) and the Henry Stratton Medal of the American Society of Hematology (1995). He earned his M.D. from Harvard Medical School in 1955. | |
| 32 | Name: | Dr. Peter Carey Nowell | | | Institution: | University of Pennsylvania | | | Year Elected: | 1993 | | | Class: | 2. Biological Sciences | | | Subdivision: | 204. Medicine, Surgery, Pathology and Immunology | | | Residency: | Resident | | | Living? : |
Deceased
| | | Birth Date: | 1928 | | | Death Date: | December 26, 2016 | | | | | | |
A professor of pathology at the University of Pennsylvania from 1964 to his retirement in 2008, Peter Carey Nowell was a creative and distinguished scholar who was internationally recognized for discovery of the Philadelphia chromosome in granulocytic leukemia - the first constant chromosomal abnormality specifically associated with any form of cancer. This discovery led to the founding of an entirely new field of research: cancer cytogenetics. Some of Dr. Nowell's other important medical discoveries are less well known. He was the first to demonstrate that bone marrow transplantation could save lethally irradiated animals, and he was also the first to show that certain sugar-containing plant products (lectins) caused white blood cells to divide, a property that has been widely used in medical research. He also proposed a widely-accepted theory to explain the evolution of malignancy among the cells of tumors. With hundreds of publications to his credit, including more than a few "citation classics," Dr. Nowell was an academic leader who has served as both director of the cancer center and chairman of pathology at the University of Pennsylvania. In 1952 he received his M.D. from the University of Pennsylvania School of Medicine, and he has worked there throughout his career. A past president of the American Society for Experimental Pathology, Dr. Nowell was also a member of the National Academy of Sciences and the recipient of awards such as the Leukemia Society of America's Robert de Villiers Award (1987), the Memorial Sloan Kettering Cancer Center's Fred W. Stewart Award (1989), and the Franklin Institute's Benjamin Franklin Medal in Life Science (2009). Peter Nowell died December 26, 2016, at age 88. | |
| 33 | Name: | Dr. Olufunmilayo Olopade | | | Institution: | University of Chicago | | | Year Elected: | 2011 | | | Class: | 2. Biological Sciences | | | Subdivision: | 204. Medicine, Surgery, Pathology and Immunology | | | Residency: | Resident | | | Living? : |
Living
| | | Birth Date: | 1957 | | | | | | |
Olufunmilayo Olopade occupies a unique place in medicine. Born and educated in Nigeria, where she earned her M.D. from the University of Ibadan in 1980, she has been on the faculty of University of Chicago since 1986. She specializes in cancer risk assessment prevention, early detection and treatment of aggressive breast cancer that disproportionately affects young women. Olopade has done pioneering work in genomic analysis of breast cancer, including seminal work in young Nigerian breast cancer patients harboring BRCA1 and BRCA2 variants. This work in comparative genomics has the potential to reduce the burden of cancer and improve health in developing nations. She has been recognized with many honors, including the Distinguished Clinical Scientist Award of the Doris Duke Charitable Foundation in 2000, a MacArthur Fellowship in 2005, and the 2017 Mendel Medal Lecture at Villanova University. She is a member of a number of scholarly communities, including the American Association for Cancer Research, the Association of American Physicians (2005), the National Academy of Sciences (2008), the Institute of Medicine (2008), and the American Academy of Arts & Sciences (2010). She was elected a member of the American Philosophical Society in 2011. | |
| 34 | Name: | Dr. Stuart H. Orkin | | | Institution: | Harvard University; Howard Hughes Medical Institute | | | Year Elected: | 2017 | | | Class: | 2. Biological Sciences | | | Subdivision: | 204. Medicine, Surgery, Pathology and Immunology | | | Residency: | Resident | | | Living? : |
Living
| | | Birth Date: | 1946 | | | | | | |
Stuart Orkin has made pioneering achievements in defining the molecular basis of blood disorders and fundamental regulatory mechanisms governing the development of blood stem cells and blood lineages. His research is unmatched for its combined impact on our understanding of the genetic basis of blood diseases, the control of hematopoiesis, and the basis of the human fetal (HbF) to adult hemoglobin switch. He provided the first comprehensive molecular dissection of an inherited disorder, the thalassemia syndromes, and isolated the first regulator of blood cell development (GATA1). He identified the first disease gene (X-linked chronic granulomatous disease) through positional cloning. In the past decade, he defined how HbF is silenced in adult red cells starting with genome-wide association studies (GWAS) through to gene editing, work that forms the basis for therapeutic trials to reactivate HbF in thalassemia and sickle cell disease patients. His research is a paradigm for the application of molecular genetics to medicine. In 2018 he was the recipient of the Mecthild Esser Nemmers Prize in Medical Science, in 2020 he was awarded the King Faisal Prize in Medicine, and in 2021 he was awarded the 2021 Gruber Genetics Prize. | |
| 35 | Name: | Sir Keith Peters | | | Institution: | University of Cambridge & Christ's College | | | Year Elected: | 1999 | | | Class: | 2. Biological Sciences | | | Subdivision: | 204. Medicine, Surgery, Pathology and Immunology | | | Residency: | International | | | Living? : |
Living
| | | Birth Date: | 1938 | | | | | | |
Sir Keith Peters received his M.B. B.Ch. in Wales. He was a MRC clinical research fellow at the University of Birmingham and National Institute for Medical Research, London. He served as a lecturer in medicine at the Welsh National School of Medicine, honorary senior registrar in medicine at United Cardiff Hospitals, and professor of medicine and director of the department of medicine at the Royal Postgraduate Medical School. He is currently the Regius Professor of Physics and Head of the Clinical School at the University of Cambridge and a Fellow of Christ's College. He was honored as Knight Bachelor in 1993 and FRS in 1995. He is a member of the Academia Europaea, Association of Physicians, Association of American Physicians, British Society for Immunology, European Society of Clinical Investigation, Scandinavian Society for Immunology, and a foreign member of the National Academy of Sciences. Sir Keith Peters is the preeminent physician-scientist in the UK. His principle scientific contributions relate to kidney disease and, in particular, the immunopathology and therapy for nephritis. He utilized the technique of plasmaphoresis and demonstrated its usefulness in the arrest of certain immunologically related diseases. His scientific contributions to medicine earned him election to the Royal Society, an unusual honor for one who is predominately a clinical scientist. This honor represents only one aspect of Sir Keith's contribution to medicine and science. He has trained many of the current leaders in UK academic medicine and has transformed the Cambridge Medical Schools, not only by the erection of new buildings but by elegant and successful recruitment to Cambridge of scientifically committed physicians. The intellectual merger of medicine in Cambridge with the existing strengths in the biological sciences has now positioned Cambridge as the leading academic medical center in Europe. That he serves on the Gairdner Foundation Award Committee and the General Motors Cancer Research Foundation reflects the high opinion that Sir Keith enjoys in this country as well. He was elected as a member of the American Philosophical Society in 1999. | |
| 36 | Name: | Dr. Jonathan E. Rhoads | | | Institution: | University of Pennsylvania | | | Year Elected: | 1958 | | | Class: | 2. Biological Sciences | | | Subdivision: | 204. Medicine, Surgery, Pathology and Immunology | | | Residency: | Resident | | | Living? : |
Deceased
| | | Birth Date: | 1907 | | | Death Date: | January 3, 2002 | | | | |
| 37 | Name: | Dr. Frederick C. Robbins | | | Institution: | Case Western Reserve University | | | Year Elected: | 1972 | | | Class: | 2. Biological Sciences | | | Subdivision: | 204. Medicine, Surgery, Pathology and Immunology | | | Residency: | Resident | | | Living? : |
Deceased
| | | Birth Date: | 1916 | | | Death Date: | August 4, 2003 | | | | |
| 38 | Name: | Dr. Seymour I. Schwartz | | | Institution: | University of Rochester | | | Year Elected: | 2001 | | | Class: | 2. Biological Sciences | | | Subdivision: | 204. Medicine, Surgery, Pathology and Immunology | | | Residency: | Resident | | | Living? : |
Deceased
| | | Birth Date: | 1928 | | | Death Date: | August 28, 2020 | | | | | | |
Seymour I. Schwartz was the Distinguished Alumni Professor of Surgery at the University of Rochester School of Medicine and Dentistry and was Chair of the Department of Surgery from 1987-1998. He received his medical training from New York University. Dr. Schwartz has authored or edited several surgical textbooks, including seven editions of the most widely read Principles of Surgery, and is Editor Emeritus of the Journal of the American College of Surgeons. His many contributions were recognized in 1992 when he was awarded the Albert Kaiser Medal. Dr. Schwartz is also a cartographic historian and has authored Mapping of America 1980), The French and Indian War (1995), An Englishman\'s Journey Along American\'s Eastern Waterway\'s (2000), This Land is Your Land: The Geographic Evolution of the United States (2000), Putting \"America\" on the Map (2007) and Gifted Hands (2009). He was on the Board of the National Museum of American History of the Smithsonian Institution and the Phillips Society of the Library of Congress. He was elected a member of the American Philosophical Society in 2001. Seymour Schwartz died on August 28, 2020 at his son's home in St. Louis, Missouri. | |
| 39 | Name: | Dr. Thomas E. Starzl | | | Institution: | University of Pittsburgh School of Medicine | | | Year Elected: | 1999 | | | Class: | 2. Biological Sciences | | | Subdivision: | 204. Medicine, Surgery, Pathology and Immunology | | | Residency: | Resident | | | Living? : |
Deceased
| | | Birth Date: | 1926 | | | Death Date: | March 4, 2017 | | | | | | |
Thomas E. Starzl was director emeritus of the Thomas E. Starzl Transplantation Institute of the University of Pittsburgh and the University of Pittsburgh Medical Center at the time of his death March 4, 2017, at age 90. He received his Ph.D. in neurophysiology and his M.D. degrees at Northwestern University. Completing surgical training at The Johns Hopkins University and the University of Miami, he became a Markle Scholar and faculty member at Northwestern University. In 1962, shortly after joining the faculty at the University of Colorado, Dr. Starzl performed his first kidney transplant and subsequently the world's first human liver transplant. Within a year, he had more kidney transplant recipients surviving than all other surgeons combined. He improved immunosuppression with anti-lymphocyte globulin (ALG), cyclosporine-based treatment and tacrolimus. Largely through Dr. Starzl's efforts, transplantation of all organs came of age. Dr. Starzl joined the University of Pittsburgh faculty in 1981and performed the first of 30 liver transplants at the university that year, helping make the city the "transplant capital of the world." Retiring from clinical practice in 1991, Dr. Starzl (in collaboration with fellow APS member and Nobel laureate Rolf Zinkernagel) delineated the previously enigmatic mechanisms of organ engraftment and proposed radical modifications of immunosuppression strategy that facilitates these mechanisms. This work served to improve clinical outcomes as well as the overall understanding of the function of the immune system. In recognition of his groundbreaking work, he was awarded the Jonathan E. Rhoads Medal for Distinguished Service to Medicine in 2002 and the National Medal of Science, the nation's highest scientific honor, in 2004. He received many other honors and awards, including the 2012 Lasker Award and the Blumberg Award from the Hepatitis B Foundation (2014), as well as 24 honorary doctorates from around the world. He published almost 2,200 scientific articles and four books, including his memoir entitled The Puzzle People: Memoirs of a Transplant Surgeon. Thomas Starzl was elected to membership in the American Philosophical Society in 1999. In 2016 the Society presented him with the Benjamin Franklin Medal for Distinguished Achievement in Science. The citation read, "Tom Starzl has transformed human organ transplantation from science fiction to reliable treatment of fatal diseases, virtually changing medical practice. Fifty years ago when the world had only a handful of surviving kidney transplant recipients he showed that rejection was reversible, allowing consistent success. His introduction of new immunosuppressive agents helped him to accomplish the first liver and multivisceral transplants. His studies explain liver regeneration and determine that this organ controls lipid metabolism. His discovery of persistent donor cell chimerism in successful recipients points the way to allograft tolerance without chronic immunosuppression. In recognition of his profound contributions the American Philosophical Society salutes Thomas E. Starzl by awarding him its highest honor." | |
| 40 | Name: | Dr. Lewis Thomas | | | Institution: | Sloan-Kettering; Cornell University Medical College | | | Year Elected: | 1976 | | | Class: | 2. Biological Sciences | | | Subdivision: | 204. Medicine, Surgery, Pathology and Immunology | | | Residency: | Resident | | | Living? : |
Deceased
| | | Birth Date: | 1913 | | | Death Date: | 12/3/93 | | | | |
| |